Discovery of pyrrole derivatives for the treatment of glioblastoma and chronic myeloid leukemia

Long-term survivors of glioblastoma multiforme (GBM) are at high risk of developing second primary neoplasms, including leukemia. For these patients, the use of classic tyrosine kinase inhibitors (TKIs), such as imatinib mesylate, is strongly discouraged, since this treatment causes a tremendous increase of tumor and stem cell migration and invasion. We aimed to develop agents useful for the treatment of patients with GBM and chronic myeloid leukemia (CML) using an alternative mechanism of action from the TKIs, specifically based on the inhibition of tubulin polymerization. Compounds 7 and 25, as planned, concentration of 100 mM.

European Journal of Medicinal Chemistry 221 (2021) 113532

Lascia un commento

Il tuo indirizzo email non sarà pubblicato.